Summary:
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate
Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of TAK-831 in Adjunctive
Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
Qualified Participants Must:
• 1. The subject is male or female and aged 18 to 50 years
•
2. The subject has a current diagnosis of schizophrenia
Qualified Participants May Receive:
Compensation for time and travel